Dietary butyrate salts (esters)
The long-chain fatty acid tributyrate composition generated by transesterification technology solves the problem of poor sensory quality of existing butyrate (esters) in dietary supplements, and achieves improving odor and taste, reducing bitterness and improving The intestinal delivery efficiency of butyrate (ester).
Patent Information
- Application Number
- CN202411061660.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-20
- Filing Date
- 2019-05-21
- Publication Date
- 2024-11-19
AI Technical Summary
Existing butyrates (esters) have negative sensory qualities in food, such as vomit, feces, and cheese-like aroma properties, which make it difficult to use in dietary supplements, especially in pediatric populations.
A triglyceride composition containing 16 to 20 carbons of long chain fatty acids was developed to generate triglycerides with butyrate moieties that improve odor and taste by transesterification technology for use as butyrate salts ( esters) are used in nutritional compositions, dietary supplements and infant formula foods.
The composition exhibits a low degree of gastric lipolysis and can effectively deliver butyric acid to the intestinal compartment, improving the sensory properties of butyrate (esters), reducing bitterness, and improving its acceptable in dietary supplements sex.
Smart Images

Figure CN118976020A_ABST
Abstract
Description
[0001] The applicant submitted a PCT application PCT / EP2019 / 063048 with the invention title of “Dietary Butyrate” on May 21, 2019. The PCT application entered the Chinese national phase on November 9, 2020 with the application number 201980031211.2. This application is a divisional application of the Chinese application. Technical Field
[0002] The present invention relates to dietary sources of butyrate having improved organoleptic properties. Background Art
[0003] Salts and esters of butyric acid are called butyrates or butanoates. Butyric acid in ester form is present in many foods, such as milk, especially milk of goats, sheep, cattle, camels and buffaloes, and dairy products such as butter and cheeses such as Parmesan cheese. Butyric acid is also a product of anaerobic fermentation, for example, as a product of fermentation produced by intestinal microflora.
[0004] The multiple beneficial effects of butyrate are well documented in mammals and livestock. At the intestinal level, butyrate modulates transepithelial fluid transport, mucosal inflammation and oxidative status, enhances intestinal barrier function, and influences visceral sensitivity and intestinal motility.
[0005] Butyrate has been shown to improve the intestinal structure of piglets with short bowel syndrome (Bartholome et al., J of Parenter Enteral Nutr., 2004, Vol. 28, No. 4, pp. 210-222), and reduce the proliferation of colon cancer cells in human cell lines (Lupton, J Nutr., 2004, Vol. 134, No. 2, pp. 479-482). The production of volatile fatty acids such as butyrate from fermentable fiber may contribute to the role of dietary fiber in colon cancer (Lupton, The Journal of Nutrition., Vol. 134, No. 2, pp. 479-482). Short-chain fatty acids (SCFAs) including but not limited to acetate, propionate and butyrate are produced by colonic bacteria that ingest or ferment non-digestible fiber and / or prebiotics. SCFAs, and most notably butyrate, promote regulatory T cells in the colon via histone deacetylase inhibition at the Foxp3 locus (Furusawa Y et al., Nature, 2013, Vol. 504, No. 7480, pp. 446-450). Oral butyrate supplementation promotes the antibacterial activity of intestinal macrophages and limits bacterial diffusion beyond the intestinal barrier. Butyrate also benefits colonocytes by increasing energy production. In addition, butyrate has been shown to reduce the incidence of diarrhea (Berni Canani et al., Gastroenterol., 2004, Vol. 127, No. 2, pp. 630-634), improve gastrointestinal symptoms in individuals with diarrhea-predominant irritable bowel syndrome (Scarpellini et al., Dig Liver Dis., 2007, Vol. 1, No. 1, pp. 19-22) and enhance the development of the small intestine in newborn piglets (Kotunia et al., J Physiol Pharmacol., 2004, Vol. 55, No. 2, pp. 59-68).
[0006] Tributyrin is a triglyceride composed of three ester functional groups, with three butyrate moieties and a glycerol backbone. Under hydrolytic conditions, such as those occurring during digestion, tributyrin may be a source of three moles of butyric acid per mole of tributyrin. However, the efficacy of tributyrin may be limited by its rapid gastric lipolysis.
[0007] Butyric acid and tributyrin are generally regarded as safe (GRAS) (21 CFR582.60 and 21 CFR184.1903, respectively) food additives and are natural components of many dairy products. However, butyric acid is associated with negative organoleptic qualities, such as vomit-like, fecal-like, and cheese-like aroma attributes. Tributyrin also has negative organoleptic qualities, particularly high bitterness. These unpleasant taste and odor attributes can make oral administration of compositions containing these compounds particularly difficult, especially in the pediatric population.
[0008] It would therefore be beneficial to provide a food grade butyrate source with improved organoleptic properties compared to available solutions. Liquid forms would provide further benefits due to ease of formulation and reduced solubility and homogenisation issues. Summary of the invention
[0009] The present invention provides compounds as a source of butyrates having improved organoleptic properties. Specifically, the compounds have improved odor and / or taste relative to butyric acid, butyrate and tributyrin. The compounds can be used as a dietary source of butyric acid. The compounds can be used, for example, in nutritional compositions, dietary supplements, infant formulas and follow-on formulas.
[0010] Advantageously, it has been found that the compounds of the present invention exhibit a low degree of gastric lipolysis and can provide efficient delivery of butyrate to the intestinal compartment.
[0011] According to a first aspect of the present invention, there is provided the use of a compound of the formula or a combination thereof for providing a butyric acid or butyrate source with improved organoleptic properties,
[0012]
[0013] Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0014] The compounds of formula (1), (2), (3) and / or (4) may be present, for example, in a composition such as a nutritional formulation, a dietary supplement, an infant formula or a follow-on formula.
[0015] In one embodiment, the improved organoleptic property is improved smell. In one embodiment, the improved organoleptic property is improved taste. In one embodiment, the improved organoleptic property is improved smell and improved taste. In one embodiment, the improved taste is reduced bitterness.
[0016] According to another aspect of the present invention, a dietary supplement for providing a source of butyrate or butyric acid is provided, the dietary supplement comprising a compound having the following formula or a combination thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0017]
[0018] The dietary supplement may be in the form of, for example, capsules, tablets, sachets, liquids / oils or powders.
[0019] According to another aspect of the present invention, there is provided an infant formula or follow-on formula comprising a compound having the formula, or a combination thereof,
[0020]
[0021] Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0022] According to another aspect of the present invention there is provided the use of an infant formula or follow-on formula of the present invention for providing a source of butyrate or butyric acid having improved organoleptic properties.
[0023] According to another aspect of the present invention, there is provided a compound having the formula
[0024]
[0025] or a combination thereof for improving or maintaining gastrointestinal (GI) health, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0026] According to another aspect of the present invention, there is provided a method for improving or maintaining GI health in a patient, the method comprising administering to the patient an effective amount of
[0027] A compound or a combination thereof, wherein R 1, R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0028] In one embodiment, the combination of a compound of formula (1) and a compound of formula (2) is used as defined herein, or is present in a composition as defined herein (e.g., a nutritional composition, a dietary supplement, an infant formula or an follow-on formula). Preferably, the compound of formula (1) is present in an amount of at least 10% by weight of the total triglycerides in the composition, and the compound of formula (2) is present in an amount of at least 10% by weight of the total triglycerides in the composition.
[0029] In one embodiment, the combination of a compound of formula (1) and a compound of formula (2) is used as defined herein, or is present in a composition as defined herein (e.g., a nutritional composition, a dietary supplement, an infant formula or an follow-on formula), wherein the compound of formula (1) is present in an amount of at least 10% by weight of the total butyric acid-containing triglycerides in the composition and the compound of formula (2) is present in an amount of at least 10% by weight of the total butyric acid-containing triglycerides in the composition.
[0030] In another embodiment, a combination of a compound of formula (1) and a compound of formula (2) is used as defined herein, or is present in a composition as defined herein (e.g., a nutritional composition, a dietary supplement, an infant formula or an follow-on formula), wherein the compound of formula (1) is present in an amount of at least 15% by weight of the total butyric acid-containing triglycerides in the composition and the compound of formula (2) is present in an amount of at least 15% by weight of the total butyric acid-containing triglycerides in the composition.
[0031] In one embodiment, the combination of a compound of formula (1), a compound of formula (2), a compound of formula (3) and a compound of formula (4) is used as defined herein or is present in a composition, nutritional composition, dietary supplement, infant formula or follow-on formula as defined herein.
[0032] In one embodiment, R as defined herein 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 It is an unsaturated fatty acid, preferably a monounsaturated fatty acid.
[0033] In one embodiment, R as defined herein 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 Selected from oleic acid, palmitic acid, stearic acid or linoleic acid.
[0034] In one embodiment, R as defined herein 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 For oleic acid.
[0035] In one embodiment, R as defined herein 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 Palmitic acid.
[0036] In one embodiment, compound (1) is 1,3-dibutyryl-2-palmitoylglycerol.
[0037] In one embodiment, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Each of which is oleic acid.
[0038] In one embodiment, the compound having formula (1) is:
[0039]
[0040] In one embodiment, the compound having formula (2) is:
[0041]
[0042] In one embodiment, the compound having formula (3) is:
[0043]
[0044] In one embodiment, the compound having formula (4) is:
[0045]
[0046] According to another aspect of the present invention, there is provided a composition comprising a compound having the formula
[0047]
[0048] wherein the compound of formula (5) comprises at least 10 weight % of the total triglycerides in the composition, and the compound of formula (6) comprises at least 10 weight % of the total triglycerides in the composition.
[0049] In one embodiment, the compound of formula (5) comprises at least 15% by weight of the total triglycerides in the composition, and the compound of formula (6) comprises at least 15% by weight of the total triglycerides in the composition.
[0050] In one embodiment, the compound of formula (5) comprises at least 15% by weight of the total triglycerides in the composition, and the compound of formula (6) comprises at least 20% by weight of the total triglycerides in the composition.
[0051] In one embodiment, the compound of formula (5) comprises at least 20 weight percent of the total triglycerides in the composition, and the compound of formula (6) comprises at least 20 weight percent of the total triglycerides in the composition.
[0052] In one embodiment, the compound of formula (5) comprises about 15% to about 30% by weight of the total triglycerides in the composition, and the compound of formula (6) comprises about 20% to about 30% by weight of the total triglycerides in the composition.
[0053] In one embodiment, the composition further comprises a compound having the formula
[0054]
[0055] Preferably, the compound of formula (7) accounts for at least 2% or 3% by weight of the total triglycerides in the composition, and / or further comprises a compound of formula
[0056]
[0057] Preferably, the compound of formula (8) comprises at least 2% or 3% by weight of the total triglycerides in the composition.
[0058] According to another embodiment of the present invention, there is provided a composition comprising a compound having the formula
[0059]
[0060] wherein the compound of formula (5) comprises at least 10 weight % of the total butyrate-containing triglycerides in the composition, and the compound of formula (6) comprises at least 10 weight % of the total butyrate-containing triglycerides in the composition.
[0061] In one embodiment, the compound of formula (5) comprises at least 15% by weight of the total butyrate-containing triglycerides in the composition, and the compound of formula (6) comprises at least 15% by weight of the total butyrate-containing triglycerides in the composition.
[0062] In one embodiment, the compound of formula (5) comprises at least 15 wt %, preferably at least 20 wt % of the total butyrate-containing triglycerides in the composition, and the compound of formula (6) comprises at least 20 wt %, preferably at least 25 wt % of the total butyrate-containing triglycerides in the composition.
[0063] In one embodiment, the composition further comprises a compound of formula (7), preferably wherein the compound of formula (7) accounts for at least 2 wt% or 3 wt% of the total butyrate-containing triglycerides in the composition, and / or further comprises a compound of formula (8), preferably wherein the compound of formula (8) accounts for at least 2 wt% or 3 wt% of the total butyrate-containing triglycerides in the composition.
[0064] The composition of the present invention may also include 1,3-dibutyryl-2-linoleoyl glycerol, 1,3-dibutyryl-2-stearoyl glycerol, 1-butyryl-2-oleoyl-3-palmitoyl glycerol, 1-palmitoyl-2-oleoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-linoleoyl glycerol, 1-linoleoyl-2-oleoyl-3-butyryl glycerol, 1-oleoyl-2-butyryl-3-linoleoyl glycerol, 1-linoleoyl-2-oleoyl-3-butyryl glycerol, 1-linoleoyl-2-butyryl-3-linoleoyl glycerol, 1-linoleoyl-2-butyryl-3-oleoyl glycerol, 1-butyryl-2-linoleoyl- 3-oleoyl glycerol, 1-oleoyl-2-linoleoyl-3-butyryl glycerol, 1-butyryl-2-stearoyl-3-oleoyl glycerol, 1-oleoyl-2-stearoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-stearoyl glycerol, 1-stearoyl-2-oleoyl-3-butyryl glycerol, 1,2-dioleoyl-3-palmitoyl glycerol, 1-palmitoyl-2,3-dioleoyl glycerol, 1,2-dioleoyl-3-linoleoyl glycerol and / or 1-linoleoyl-2,3-dioleoyl glycerol.
[0065] The composition of the present invention may be in the form of a nutritional composition.
[0066] The composition of the present invention may be in the form of an infant formula or a follow-on formula.
[0067] The composition of the present invention may be in the form of a dietary supplement.
[0068] According to another aspect of the present invention there is provided the use of a composition as defined herein for providing a source of butyrate or butyric acid having improved organoleptic properties.
[0069] According to another aspect of the present invention, there is provided a method of providing a source of butyrate having improved organoleptic properties to an individual, the method comprising administering to the individual an effective amount of a composition as defined herein.
[0070] According to another aspect of the present invention there is provided a composition as defined herein for use in improving or maintaining gastrointestinal health.
[0071] According to another aspect of the present invention, there is provided a method of improving or maintaining gastrointestinal health in an individual, the method comprising administering to the individual an effective amount of a composition as defined herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 Shown is the release of fatty acids from an emulsion containing 200 mg of a mixture of (A) tributyrin, (B) high oleic sunflower oil and (C) triacylglycerols (TAGs) containing a butyrate fraction according to the present invention, digested with (i) simulated intestinal fluid (SIF) or (ii) sequentially with gastric fluid (SGF) and simulated intestinal fluid (SIF).
[0073] Figure 2 The overall extent of lipid digestion of a mixture of tributyrin, high oleic sunflower oil and TAGs containing a butyrate fraction according to the invention after both SIF and SGF-SIF is shown. DETAILED DESCRIPTION
[0074] Triglycerides
[0075] Triglycerides (also called triacylglycerols) are triesters derived from glycerol and three fatty acids.
[0076] Fatty acids are carboxylic acids with a long tail (chain). Fatty acids can be unsaturated or saturated. Fatty acids that are not attached to other molecules are called free fatty acids (FFA).
[0077] The term "fatty acid moiety" refers to the portion of a triglyceride produced from a fatty acid in an esterification reaction with glycerol. The triglycerides used in the present invention contain at least one butyric acid moiety and at least one long chain fatty acid moiety.
[0078] Preferred long chain fatty acids for use in the present invention are fatty acids having 16 to 20 carbon atoms.
[0079] Examples of long-chain fatty acids include oleic acid, palmitic acid, stearic acid, and linoleic acid.
[0080] The triglyceride of the present invention can be synthesized by, for example, esterification of long-chain fatty acids and butyric acid with glycerol.
[0081] The triglycerides of the present invention can be synthesized by, for example, transesterification between tributyrin and another triglyceride containing long-chain fatty acids. In one embodiment, high oleic sunflower oil is the source of long-chain fatty acids. This produces triglycerides containing mainly butyrate and oleate moieties. Oleic acid is the main fatty acid present in breast milk. These compounds are dairy-free, cholesterol-free and vegan. The fatty acids are released from the triglycerides due to lipases naturally present in the gastrointestinal tract. Relative to butyrate, these compounds do not add additional mineral salts to the final formulation.
[0082] Alternative triglyceride synthesis methods can be routinely determined by those skilled in the art. By way of example, a method for obtaining 1,3-dibutyryl-2-palmitoylglycerol (BPB) is as follows:
[0083]
[0084] Triglycerides containing a single butyrate moiety may be used herein. Alternatively, mixtures of triglycerides containing different butyrate moieties may be used.
[0085] Composition
[0086] The present invention provides a composition comprising a triglyceride containing a butyrate moiety as mentioned herein. The composition may be, for example, a nutritional composition, a dietary supplement, an infant formula or an follow-on formula.
[0087] The expression "nutritional composition" refers to a composition that supplies nutrients to an individual. Such a nutritional composition is preferably orally administered and may comprise a lipid or fat source and a protein source. It may also contain a carbohydrate source. In one embodiment, the nutritional composition contains only a lipid or fat source. In other specific embodiments, the nutritional composition may comprise a lipid (or fat) source and a protein source, a carbohydrate source, or both.
[0088] In some embodiments, the nutritional composition according to the invention is an "enteral nutritional composition", i.e., it involves a food material to be administered in the gastrointestinal tract. Gastric introduction may involve the use of a tube passed through the oral / nasal passages or a tube in the abdomen directly to the stomach. This may be used in particular in a hospital or clinic.
[0089] The composition according to the invention may be an infant formula (eg a first stage infant formula), a second stage or follow-on formula, a growing-up milk, a baby food, an infant cereal composition, a fortifier (such as a human milk fortifier) or a supplement.
[0090] The expression "infant formula" as used herein means a food intended for the nutrition of infants in the first few months of life and which meets the multiple nutritional requirements of such persons (e.g. in accordance with Article 2(c) of Council Directive 91 / 321 / EEC 2006 / 141 / EC of 22 December 2006 on infant formula and follow-on formula).
[0091] Generally speaking, stage 1 infant formula is used as a breast milk substitute for infants from birth. Stage 2 or follow-on infant formula is provided from the 6th month onwards. Infant formula constitutes the main liquid element in the gradually diversified diet of such people. "Growing-up milk" (or GUM) is provided from the age of one year. It is usually a milk-containing beverage adapted to the specific nutritional needs of young children.
[0092] The term "fortifier" relates to a liquid or solid nutritional composition suitable for mixing with breast milk (human milk) or infant formula.The term "breast milk" is to be understood as mother's breast milk or mother's colostrum, or donor's breast milk or donor's colostrum.
[0093] The term "dietary supplement" can be used to supplement an individual's nutrition (it is usually used as such, but it can also be added to any kind of composition intended for ingestion). The supplement can be in tablet, capsule, lozenge or liquid form, for example. The supplement can also contain protective hydrophilic colloids (such as gums, proteins, modified starches), binders, film formers, encapsulating agents / materials, wall / shell materials, matrix compounds, coatings, emulsifiers, surfactants, solubilizers (oils, fats, waxes, lecithins, etc.), adsorbents, carriers, fillers, co-compounds, dispersants, wetting agents, processing aids (solvents), flow agents, taste masking agents, weighting agents, gelling agents and gel forming agents. Dietary supplements may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including but not limited to: water, gelatin from any source, vegetable gums, lignin sulfonates, talc, sugars, starches, gum arabic, vegetable oils, polyalkylene glycols, flavors, preservatives, stabilizers, emulsifiers, buffers, lubricants, colorants, wetting agents, fillers, etc.
[0094] In another specific embodiment, the nutritional composition of the present invention is a fortifier. The fortifier can be a breast milk fortifier or a formula fortifier, such as an infant formula fortifier. Therefore, when the infant or toddler is premature, the fortifier is a particularly advantageous embodiment.
[0095] When the composition is a supplement, it may be provided in unit dosage form.
[0096] The nutritional composition of the present invention, especially infant formula, typically comprises a protein source, a carbohydrate source and a lipid source. However, in some embodiments, particularly if the nutritional composition of the present invention is a supplement or fortifier, only lipid (or lipid source) may be present.
[0097] The nutritional composition according to the present invention may contain a protein source. The amount of protein may be 1.6 g / 100 kcal to 3 g / 100 kcal. In some embodiments, particularly when the composition is used for premature infants / young children, the amount of protein may be between 2.4 g / 100 kcal and 4 g / 100 kcal or higher than 3.6 g / 100 kcal. In some other embodiments, the amount of protein may be lower than 2.0 g / 100 kcal, for example, between 1.8 g / 100 kcal and 2 g / 100 kcal, or the amount may be lower than 1.8 g / 100 kcal.
[0098] Protein sources based on, for example, whey, casein and mixtures thereof can be used, as well as plant-based (e.g., soy-based) protein sources. With regard to whey protein of interest, the protein source can be based on acid whey or sweet whey or a mixture thereof, and can contain alpha-lactalbumin and beta-lactoglobulin in any desired proportion. In some embodiments, the protein source is mainly whey (i.e., more than 50% of the protein comes from whey protein, such as 60%> or 70%>). The protein can be intact or hydrolyzed, or a mixture of intact protein and hydrolyzed protein. The so-called term "intact" means that the main part of the protein is intact, i.e., the molecular structure has not changed, for example, at least 80% of the protein has not changed, such as at least 85% of the protein has not changed, preferably at least 90% of the protein has not changed, even more preferably at least 95% of the protein has not changed, such as at least 98% of the protein has not changed. In a specific embodiment, 100% of the protein has not changed.
[0099] The term "hydrolyzed" means in the context of the present invention that a protein has been hydrolyzed or broken down into its constituent amino acids.
[0100] The protein may be fully hydrolyzed or partially hydrolyzed. If hydrolyzed protein is desired, a hydrolysis process may be performed as desired and as known in the art. For example, a whey protein hydrolyzate may be prepared by enzymatic hydrolysis of the whey fraction in one or more steps. If the whey fraction used as a raw material is substantially lactose-free, it is found that the protein undergoes much less lysine blockage during the hydrolysis process. This makes it possible to reduce the degree of lysine blockage from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example, about 7% by weight of lysine, which greatly improves the nutritional quality of the protein source.
[0101] In a specific embodiment, the protein of the composition is hydrolyzed, fully hydrolyzed or partially hydrolyzed. The degree of hydrolysis (DH) of the protein may be between 2 and 20, between 8 and 40, between 20 and 60, between 20 and 80, or greater than 10, 20, 40, 60, 80 or 90. For example, a nutritional composition containing a hydrolyzate having a degree of hydrolysis of less than about 15% is available from Nestle Company under the trademark Commercially available.
[0102] At least 70%, 80%, 85%, 90%, 95% or 97% of the protein may be hydrolyzed. In a particular embodiment, 100% of the protein is hydrolyzed.
[0103] In a specific embodiment, the protein of the composition is a plant-based protein.
[0104] The nutritional composition according to the present invention may include a carbohydrate source. This is particularly preferred when the nutritional composition of the present invention is an infant formula. In this case, any carbohydrate source commonly present in infant formula, such as lactose, sucrose, sucrose, maltodextrin, starch and mixtures thereof, may be used, but one of the preferred carbohydrate sources of infant formula is lactose. The nutritional composition of the present invention may also contain all vitamins and minerals that are considered necessary for daily diet and in significant amounts of nutrition. The minimum requirements of certain vitamins and minerals have been determined. Examples of minerals, vitamins and other nutrients optionally present in the composition of the present invention include vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorus, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine and L-carnitine. Minerals are usually added in the form of salts. The presence and amount of specific minerals and other vitamins will vary depending on the target group. If necessary, the nutritional composition of the present invention may contain emulsifiers and stabilizers, such as soy, lecithin, citric acid monoglyceride and citric acid diglyceride, etc. The nutritional composition of the present invention may also contain other substances that may have beneficial effects, such as lactoferrin, osteopontin, TGFbeta, slgA, glutamine, nucleotides, nucleosides, etc.
[0105] The composition of the invention may also comprise at least one non-digestible oligosaccharide (eg prebiotic), typically in an amount between 0.3% and 10% by weight of the composition.
[0106] Prebiotics are generally non-digestible in the sense that they are not broken down and absorbed in the stomach or small intestine, and thus they can remain intact as they pass through the stomach and small intestine to the colon, where they are selectively fermented by beneficial bacteria. Examples of prebiotics include certain oligosaccharides, such as fructooligosaccharides (FOS), inulin, xylooligosaccharides (XOS), polydextrose, or any mixture thereof. In a specific embodiment, the prebiotic may be fructooligosaccharides and / or inulin. In a specific embodiment, the prebiotic is a combination of FOS and inulin, such as in the product sold by BENEO-Orafti under the trademark Fructo-oligosaccharides (formerly ) or sold by BENEO-Orafti under the trademark Inulin (formerly ). Another example is a combination of 70% short chain oligofructose and 30% inulin, which is registered by Nestle under the trademark "Prebio1". The nutritional composition of the present invention may also include at least one milk oligosaccharide, which may be a BMO (bovine milk oligosaccharide) and / or an HMO (human milk oligosaccharide). The composition of the present invention may also include at least one probiotic (or probiotic strain), such as a probiotic bacterial strain.
[0107] The most commonly used probiotic microorganisms are mainly most bacteria and yeasts of the following genera: Lactobacillus spp., Streptococcus spp., Enterococcus spp., Bifidobacterium spp. and Saccharomyces pp.
[0108] In some embodiments, the probiotic is a probiotic bacterial strain. In some embodiments, it is a bifidobacterium and / or a lactobacillus.
[0109] Based on dry weight, the nutritional composition according to the invention may comprise 10e3 to 10e12 cfu of the probiotic strain per g of composition, more preferably between 10e7 and 10e12 cfu, such as between 10e8 and 10e10 cfu.
[0110] In one embodiment, the probiotic is live. In another embodiment, the probiotic is non-replicating or inactivated. It can also be a probiotic part, such as a cell wall component or a product of probiotic metabolism. In some other embodiments, live probiotics and inactivated probiotics can be present simultaneously. The nutritional composition of the present invention may also include at least one bacteriophage (bacteriophage) or a mixture of bacteriophages, which are preferably directed against pathogenic Streptococci, Haemophilus, Moraxella and Staphylococcus.
[0111] In one embodiment, the nutritional composition according to the present invention may be a dairy product. A dairy product is a product comprising a milk-based product. Dairy products are generally prepared from a suitable mixture of concentrated milk protein and a fat source. Dairy products may be acidified. Dairy products include ready-to-drink milk-containing beverages, concentrated milk, condensed milk, sweetened condensed milk, milk powder, yogurt, fresh cheese, cheese, ice cream, and dairy spreads, such as spreadable fresh cheese, cottage cheese, quark cheese, French cream, clotted cream and cream cheese. Milk powder can be manufactured, for example, by spray drying or by freeze drying.
[0112] Depending on their fat content, dairy products can be prepared from whole or whole milk, semi-skimmed milk, skimmed milk or low-fat milk. Skimmed milk is milk containing less than 0.1% milk fat. Semi-skimmed milk is milk containing between 1.5% and 2.5% milk fat. Typically, whole milk is milk containing 3% to 4% fat. The exact fat content of skimmed milk, semi-skimmed milk and whole milk depends mainly on local food regulations.
[0113] Dairy products are usually made from cow's milk. Dairy products can also be made from buffalo milk, yak milk, goat milk, ewe milk, mare milk, donkey milk, camel milk, reindeer milk, moose milk or a combination thereof.
[0114] Acidified dairy products can be obtained by fermentation with suitable microorganisms. Fermentation provides flavor and acidity to dairy products. It can also affect the texture of dairy products. In addition, the microorganisms used for fermentation are selected according to the ability of the microorganism to ferment milk into edible fermented dairy products. Generally, the microorganisms are known for their beneficial properties. The microorganisms include lactic acid bacteria and yeast. Some of these microorganisms can be considered as probiotics. The example of lactic acid bacteria includes Lactobacillus delbrueckii subsp.bulgaricus and Streptococcus thermophilus, both of which are related to the production of yogurt, or other lactic acid bacteria belonging to the genus Lactobacillus, Streptococcus, Lactococcus, Leuconostoc, Bifidobacterium, Pediococcus or any mixture thereof.
[0115] Another example of a fermented dairy product (also called cultured dairy product or cultured dairy or cultured milk) is cultured buttermilk fermented with Lactococcus lactis (Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar. diacetylactis) and / or Leuconostoc mesenteroides subsp. cremoris.
[0116] The microorganisms may be live or inactivated.
[0117] Dairy analogs are products prepared in a similar manner to the above-mentioned dairy products, but using (wholly or partially) non-dairy sources of protein and / or (wholly or partially) non-dairy sources of edible fat. Suitable protein sources include vegetable proteins such as soy, potato and pea. Suitable fat sources include oils and fats from plant or marine sources. Fats and oils are used as interchangeable terms. The similar preparations mentioned above are intended to include methods for products in which the traditional whey separation step is omitted because the formulation of the dairy analogs of the product allows this step to be skipped.
[0118] The nutritional composition according to the invention may be prepared in any suitable way.
[0119] For example, formula foods such as infant formula foods can be prepared by blending a protein source, a carbohydrate source, and a fat source in an appropriate ratio. If used, an emulsifier can be added at this time. Vitamins and minerals can be added at this time, but they are usually added later to avoid thermal degradation. Before blending, any lipophilic vitamins, emulsifiers, etc. can be dissolved in a fat source. Water (preferably water subjected to reverse osmosis) can then be mixed to form a liquid mixture. The water temperature is suitably in the range of about 50°C to about 80°C to help disperse the ingredients. A commercially available liquefier can be used to form a liquid mixture.
[0120] Particularly if the final product is in liquid form, any oligosaccharides may be added at this stage. If the final product is a powder, these ingredients may also be added at this stage if desired.
[0121] The liquid mixture is then homogenized, for example in two stages.
[0122] In one embodiment, the nutritional composition of the invention is administered to an infant or young child as a supplementary composition to breast milk.
[0123] The composition of the invention may be in the form of, for example, a solid (eg, powder), a liquid or a gel.
[0124] The composition of the present invention may be in the form of, for example, tablets, dragees, capsules, pellets, powders, granules, solutions, emulsions, suspensions, coated granules, spray-dried granules or pills.
[0125] The composition may be in the form of a pharmaceutical composition and may contain one or more suitable pharmaceutically acceptable carriers, diluents and / or excipients.
[0126] Examples of such suitable excipients for the compositions described herein may be found in "Handbook of Pharmaceutical Excipients", 2nd Edition, (1994), Edited by A Wade and PJ Weller.
[0127] Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro, ed., 1985).
[0128] The pharmaceutical composition may contain the following substances as carriers, excipients or diluents or in addition to carriers, excipients or diluents: any suitable binder, lubricant, suspending agent, coating agent and / or solubilizer. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose and polyethylene glycol.
[0129] Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
[0130] Preservatives, stabilizers, dyes and even flavoring agents may be provided in the composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used.
[0131] Gastrointestinal health
[0132] The compounds defined herein are sources of butyrate / butyric acid and are therefore useful for improving or maintaining gastrointestinal (GI) health.
[0133] In one embodiment, the compounds and compositions defined herein may be used to treat inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
[0134] The multiple beneficial effects of butyrate on GI health are well documented. At the intestinal level, butyrate modulates transepithelial fluid transport, mucosal inflammation and oxidative status, strengthens the epithelial barrier, and regulates visceral sensitivity and intestinal motility.
[0135] Fatty acids, including butyrate, are the main energy source for colonic mucosal cells (Roedriger, Gut., 1980, Vol. 21, pp. 793-798), and are most important for colonocytes in the distal region of the colon. A strong nutritional effect of butyrate on the small intestinal mucosa has been observed in experimental animals (Guilloteau et al., 2 J Anim Feed Sci., 2004, Vol. 13, Supplement 1, pp. 393-396). A reduction in intestinal butyrate concentrations leads to atrophy of the colonic mucosa, which is generally explained by a reduced utilization of substrates by colonocytes. On the other hand, administration of butyrate to the colonic lumen leads to weight gain, increased DNA synthesis, and increased intestinal crypt depth (Kripke et al., J Parenter Enter Nutr., 1989, Vol. 13, pp. 109-116).
[0136] High concentrations of butyrate obtained by fermentation of insoluble dietary fiber or after anal administration of butyrate can inhibit early and late stages of colon carcinogenesis by regulating the transcription, expression and activation of key proteins of the apoptotic cascade (Avivi-Green et al., J Nutr., 2002, Vol. 132, No. 7, pp. 1812-1818).
[0137] Chapman et al. (Gut, 1994, Vol. 35, No. 1, pp. 73-76) showed that inflamed colonic mucosa captures much more butyrate than glutamine or glucose. Experiments have shown that butyrate infusion leads to a significant reduction in inflammation and a reduction in the extent of ulceration in the colon wall of rats (Andoh et al., J Parenter Enter Nutr., 1999, Vol. 23, No. 5, pp. 70-73).
[0138] The effectiveness of butyrate enemas has been demonstrated by clinical observations in patients with ulcerative colitis (Han et al., Gastroenterol Clin North Am., 1999, Vol. 28, pp. 423-443; Scheppach et al., Gastroenterol Suppl., 1997, Vol. 222, pp. 53-57).
[0139] The direct anti-inflammatory activity of butyrate may be related to the inhibition of the migration of nuclear factor KappaB (NFKB) and its binding to DNA, and for the same reason, it may also inhibit the transcription and production of pro-inflammatory cytokines (Segain et al., Gut., 2000, Vol. 47, pp. 397-403).
[0140] Therefore, the triglyceride compounds used in the present invention are a source of butyrate, which can play an important role in maintaining intestinal homeostasis and GI health.
[0141] Application
[0142] Preferably, the compounds and compositions described herein are administered enterally.
[0143] Enteral administration may be, for example, oral or gastric administration.
[0144] Generally, administration of the combinations or compositions described herein may be, for example, by the oral route or another route into the gastrointestinal tract, such as by tube feeding.
[0145] The subject may be a mammal, such as a human, canine, feline, equine, caprine, bovine, ovine, porcine, cervidae, and primate. Preferably, the subject is a human.
[0146] The present invention provides the following embodiments:
[0147] 1. Use of a compound of the formula or a combination thereof for providing a butyrate source with improved sensory properties, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 independently a long chain fatty acid having 16 to 20 carbons
[0148]
[0149] 2. The use according to embodiment 1, wherein the compound or combination thereof is present in a nutritional composition, preferably a dietary supplement, an infant formula or a follow-on formula.
[0150] 3. A dietary supplement for providing a source of butyrate, the dietary supplement comprising a compound having the formula, or a combination thereof,
[0151]
[0152] Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0153] 4. The dietary supplement according to embodiment 3, which is in the form of capsules, tablets, sachets or powders.
[0154] 5. An infant formula or follow-on formula comprising a compound of the formula, or a combination thereof,
[0155]
[0156] Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0157] 6. The infant formula or follow-on formula according to embodiment 5, which is used to provide a butyrate source.
[0158] 7. Compounds having the formula
[0159]
[0160] or a combination thereof, for improving or maintaining gastrointestinal (GI) health,
[0161] Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
[0162] 8. The use according to embodiment 1 or 2, wherein a combination of a compound of formula (1) and a compound of formula (2) is used, preferably wherein the combination is present in a composition comprising a compound of formula (1) and a compound of formula (2), the amount of the compound of formula (1) being at least 10% by weight of the total triglycerides in the composition, and the amount of the compound of formula (2) being at least 10% by weight of the total triglycerides in the composition.
[0163] 9. The use according to embodiment 1 or 2, wherein a combination of a compound of formula (1) and a compound of formula (2) is used, and wherein the combination is present in a composition comprising a compound of formula (1) and a compound of formula (2), the amount of the compound of formula (1) being at least 10% by weight of the total butyrate-containing triglycerides in the composition, and the amount of the compound of formula (2) being at least 10% by weight of the total butyrate-containing triglycerides in the composition.
[0164] 10. The use according to embodiment 1, 2, 8 or 9, wherein a combination of a compound of formula (1), a compound of formula (2), a compound of formula (3) and a compound of formula (4) is used.
[0165] 11. The use according to embodiments 1, 2 or 8 to 10, the dietary supplement according to embodiments 3, 4 or 8 to 10, the infant formula or follow-on formula according to embodiments 5, 6 or 8 to 10, or the compound for use according to embodiments 7 or 8 to 10, wherein R 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 It is an unsaturated fatty acid, preferably a monounsaturated fatty acid.
[0166] 12. The use according to embodiments 1, 2 or 8 to 10, the dietary supplement according to embodiments 3, 4 or 8 to 10, the infant formula or follow-on formula according to embodiments 5, 6 or 8 to 10, or the compound for use according to embodiments 7 or 8 to 10, wherein R 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 Selected from oleic acid, palmitic acid or linoleic acid.
[0167] 13. The use according to embodiments 1, 2 or 8 to 10, the dietary supplement according to embodiments 3, 4 or 8 to 10, the infant formula or follow-on formula according to embodiments 5, 6 or 8 to 10, or the compound for use according to embodiments 7 or 8 to 10, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Each of which is oleic acid.
[0168] 14. A composition comprising a compound having the formula
[0169]
[0170] wherein the compound of formula (5) comprises at least 10 weight % of the total triglycerides in the composition, and wherein the compound of formula (6) comprises at least 10 weight % of the total triglycerides in the composition.
[0171] 15. A composition according to embodiment 14, wherein the compound of formula (5) accounts for at least 15 weight % of the total triglycerides in the composition, and wherein the compound of formula (6) accounts for at least 20 weight % of the total triglycerides in the composition.
[0172] 16. The composition according to embodiment 14 or 15, further comprising a compound having the formula
[0173]
[0174] Preferably, the compound of formula (7) accounts for at least 2% by weight of the total triglycerides in the composition, and / or further comprises a compound of formula
[0175]
[0176] Preferably, the compound of formula (8) comprises at least 2 wt% of the total triglycerides in the composition.
[0177] 17. A composition comprising a compound having the formula
[0178]
[0179] wherein the compound of formula (5) comprises at least 10 weight percent of the total butyrate-containing triglycerides in the composition, and wherein the compound of formula (6) comprises at least 10 weight percent of the total butyrate-containing triglycerides in the composition.
[0180] 18. A composition according to embodiment 17, wherein the compound of formula (5) accounts for at least 15% by weight, preferably at least 20% by weight of the total butyrate-containing triglycerides in the composition, and wherein the compound of formula (6) accounts for at least 20% by weight, preferably at least 25% by weight of the total butyrate-containing triglycerides in the composition.
[0181] 19. The composition according to embodiment 17 or 18, further comprising the compound of formula (7), preferably wherein the compound of formula (7) accounts for at least 2 weight % of the total butyrate-containing triglycerides in the composition, and / or further comprising the compound of formula (8), preferably wherein the compound of formula (8) accounts for at least 2 weight % of the total butyrate-containing triglycerides in the composition.
[0182] 20. The composition of any one of embodiments 14 to 19, further comprising 1,3-dibutyryl-2-linoleoyl glycerol, 1,3-dibutyryl-2-stearoyl glycerol, 1-butyryl-2-oleoyl-3-palmitoyl glycerol, 1-palmitoyl-2-oleoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-linoleoyl glycerol, 1-linoleoyl-2-oleoyl-3-butyryl glycerol, 1-oleoyl-2-butyryl-3-linoleoyl glycerol, 1-linoleoyl-2-butyryl-3-oleoyl glycerol, 1-butyryl-2-oleoyl-3- 1-Butyryl-2-stearoyl-3-oleoyl glycerol, 1-oleoyl-2-stearoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-stearoyl glycerol, 1-stearoyl-2-oleoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-stearoyl glycerol, 1-stearoyl-2-oleoyl-3-butyryl glycerol, 1,2-dioleoyl-3-palmitoyl glycerol, 1-palmitoyl-2,3-dioleoyl glycerol, 1,2-dioleoyl-3-linoleoyl glycerol and / or 1-linoleoyl-2,3-dioleoyl glycerol.
[0183] 21. The composition according to any one of embodiments 17 to 20, wherein the composition is a nutritional composition.
[0184] 22. The composition of any one of embodiments 14 to 20, wherein the composition is an infant formula, a follow-on formula, or a dietary supplement.
[0185] 23. Use of a composition according to any one of embodiments 14 to 22 for providing a butyrate source with improved organoleptic properties.
[0186] 24. A composition for improving or maintaining gastrointestinal health according to any one of embodiments 14 to 22.
[0187] Example
[0188] Example 1 - Preparation of triglycerides containing butyrate moieties
[0189] The composition comprising triglycerides having butyrate moieties is produced by chemical transesterification between tributyrin and high oleic sunflower oil in the presence of a catalyst such as sodium formate. A molar excess of tributyrin is used compared to the high oleic sunflower oil.
[0190] The three reagents, tributyrin, high oleic sunflower oil and catalyst, are mixed together in a reactor under a nitrogen atmosphere and then heated at 80°C for 3 hours under stirring. Once the reaction is complete, the product is washed with water and dried under vacuum (25 mbar, 60°C, 2 hours). The resulting oil product is then subjected to a decolorization step under the action of bleaching earth and purified by short-path distillation (130°C, 0.001-0.003 mbar) and / or by deodorization by injection of steam water (160°C, 2 mbar, 2 hours).
[0191] The components of the resulting oil composition (mainly triglycerides) are shown in Table 1 below. These triglycerides are represented by the three fatty acids they contain. These fatty acids are represented by their lipid numbers: butyrate is 4:0, palmitate is 16:0, stearate is 18:0, oleate is 18:1, and linoleate is 18:2. The middle fatty acid is located at the sn-2 position in the triglyceride. For example, 16:0-4:0-18:1 represents two different triglycerides that have both sn-2 butyrate and sn-1 palmitate and sn-3 oleate or sn-1 oleate and sn-3 palmitate.
[0192] Triglyceride distribution and regioisomers were analyzed by liquid chromatography coupled to a high-resolution mass spectrometer. The proportions of lipid classes were assessed by liquid chromatography coupled to an evaporative light scattering detector (ELSD).
[0193] Table 1: Triglyceride regioisomer distribution [g / 100g]
[0194] Triglyceride regioisomers [g / 100g]
[0195] Composition
[0196]
[0197] In the composition samples, the two most abundant triglycerides were 4:0-18:1-4:0 and 18:1-18:1-4:0, which together were approximately 40 g / 100 g to 50 g / 100 g.
[0198] Example 2 - Odor Properties of Triglycerides Containing Butyrate Moieties
[0199] The odor of a solution containing triglycerides with a butyrate moiety (composed primarily of oleic and butyric fatty acids) was compared to a solution containing sodium butyrate.
[0200] Sample preparation
[0201] Solutions containing triglycerides with butyrate moieties (see Example 1) or containing sodium butyrate were prepared and stored at 4° C. before delivery to the sensory panel. Each 250 mL solution contained 600 mg butyric acid (equivalent to one commercially available sodium butyrate capsule as a supplement; 2.4 mg / mL concentration) and 1% w / v BEBA Optipro 1 infant formula in acidified deionized water.
[0202] The day before the assay, samples were prepared by placing 4 mL of each solution (butyric triglyceride solution; sodium butyrate solution) into Agilent vials.
[0203] method
[0204] A "two out of five test" was performed. In this test, five samples were presented to the panelists. The panelists were instructed to identify the two samples that were different from the other three samples. The order of presentation of the samples was randomized to avoid presentation order bias.
[0205] In addition to the 2 out of 5 test, panelists were provided with a comment box to allow them to comment on the nature of the perceived difference (eg, odor intensity, odor quality).
[0206] result
[0207] The five samples were presented to the panelists simultaneously. They were asked to uncap, sniff, and then cap each vial in the given order. The results are shown in Table 2.
[0208] Table 2
[0209] Number of responses Number of correct responses Significance 11 9 p<0.0001***
[0210] P values were calculated using the binomial test performed by Fizz software (Biosystemes, France).
[0211] It was found that panelists who responded correctly (TAG containing a butyrate moiety was different from sodium butyrate) mentioned that sodium butyrate smelled like "cheese", while for the TAG samples containing a butyrate moiety, this "cheese" odor was significantly reduced and the smell was quite neutral.
[0212] Example 3 - Taste properties of triglycerides containing butyrate moieties
[0213] Solutions containing triglycerides with a butyrate moiety consisting mainly of oleic and butyric fatty acids (see Example 1) were subjected to a sensory benchmark test against solutions containing tributyrin.
[0214] Sample preparation :
[0215] One scoop (4.6 g) of BEBA Optipro 1 infant formula was added to warm water (cooled, boiled tap water as directed) to a final volume of 150 mL (approximately 3% w / v solution). Each triglyceride form of butyrate was weighed separately to deliver 600 mg butyrate, and infant formula was added to each solution to a final volume of 50 mL.
[0216] Solution A contained triglycerides having a butyrate moiety (see Example 1); and solution B contained tributyrin.
[0217] method
[0218] A group of panelists performed repeated blind tastings.
[0219] The samples were prepared immediately prior to the initial bitterness assessment and each solution was shaken vigorously. Tasting cups labeled A and B were simultaneously filled with a small amount of the respective solution.
[0220] The two samples were presented to the panelists simultaneously. They were asked to taste the solutions in small sips and rate the perceived bitterness on a scale of 0-10; where 0 is no perceived bitterness and 10 is similar to the maximum imaginable bitterness.
[0221] result
[0222] The panelists rated the bitterness of Solution A as 4.33 ± 1.52, mean ± SD.
[0223] The panelists rated the bitterness of Solution B as 8.33 ± 1.52, mean ± SD.
[0224] These data indicate that TAG compositions containing a butyrate moiety in infant formula are significantly less bitter than tributyrin.
[0225] Example 4 - Taste Properties of 1,3-Dibutyryl-2-Palmitoyl Glycerol
[0226] 1,3-Dibutyryl-2-palmitoylglycerol (BPB) was synthesized as a single compound using the following synthesis:
[0227]
[0228] BPB was evaluated in a descriptive sensory panel evaluation and found to have a neutral taste and odor.
[0229] Example 5 - Digestion of triglycerides containing butyrate moieties
[0230] 5.1 Materials
[0231] Sodium taurocholate, sodium chloride, hydrochloric acid, sodium hydroxide, potassium hydroxide, maleic acid, tris(hydroxymethyl)aminomethane, pepsin (porcine, 800-111 2500 U / mg, P7000, actual activity used was 674 U / mg and 561 U / mg), pancreatin (porcine, USP x 8, P7585), and bile extract porcine (total bile salt content = 49 wt%; with 10%-15% glycodeoxycholic acid, 3%-9% taurodeoxycholic acid, 0.5%-7% deoxycholic acid; phospholipids 5%, B8631) were used as received and purchased from Sigma-Aldrich (St Louis, MO, USA). Rabbit gastric extract (RGE 70 ≥ 70 U / mL RGL and ≥ 280 U / mL pepsin) was purchased from Lipolytech, Marseille, France. All water used in this study was of pure Milli Q quality. Tributyrin (food grade) was obtained from Sigma and high oleic sunflower oil was obtained from Florin. The interesterified triglycerides were obtained via chemical interesterification with sodium formate (obtained from Evonik) as catalyst.
[0232] 5.2 Emulsion preparation
[0233] Prepare a mixture consisting of 0.3 wt% polyoxyethylene sorbitan monooleate ( 80) A stable 10 wt% oil-in-water emulsion. The emulsion was then produced using a Hielscher UP 400S ultrasonic probe homogenizer equipped with a 5 mm diameter rod probe by applying 100% amplitude at 100% cycle for 2 minutes while cooling the sample with ice water.
[0234] 5.3 Particle size determination
[0235] The droplet size of each lipid emulsion was measured by laser scattering using a Mastersizer 3000 equipped with a Hydro SM from Malvern Instruments (Malvern, Worcestershire, United Kingdom). The laser specifications for the two lasers were 4 mW 632.8 nm and 10 mW 470 nm. To avoid multiple scattering effects, the samples were diluted to approximately 0.002 wt %. Information on the emulsion particle size was then obtained by best fit between the light scattering (Mie) theory and the measured particle size distribution. A refractive index of 1.456 and an adsorption value of 0.01 were used for the oil phase. The emulsion particle size is quoted as two values, the volume surface mean diameter D3,2 (D3,2 1 / 4Pnidi 3 / nidi 2) or volume length average diameter D4,3 (D4,3 1 / 4Pnidi 4 / nidi3). The emulsion particle size results are the average of three measurements on two freshly prepared emulsions.
[0236] 5.4 Statistical analysis
[0237] Statistical analysis was performed using the software Igor Pro and using a two-sided t-test with unequal variances.
[0238] 5.5 In vitro digestion
[0239] The lipid emulsion (2mL) containing 200mg fat is subjected to gastrointestinal in vitro lipolysis. Digestion is carried out in a constant temperature glass container (37°C) in a pH-STAT setting controlled by TIM 856 double burette pH-STAT (Radiometer Analytical, France). For gastric digestion, the sample is incubated 90 minutes at 37°C and a pH of 5.5 with 8.5mL simulated gastric fluid (SGF), which is composed of 150mM NaCl, 450U / mL pepsin, 18U / mL rabbit gastric lipase. Digestion is initiated by adding the rabbit gastric lipase of 18 tributyrin U / ml (TBU) activity (measured when pH 5.4).
[0240] The intestinal digestion step is carried out in pH stat, wherein by adding NaOH (0.05M), pH is kept constant at 6.8. Bile salt mixture (bile salt prepared with tris buffer, 5mM tris, 150mM NaCl) and calcium solution (20mM Ca, 176 5mM tris, 150mM NaCl) are added to the SGF sample mixture. The mixture is transferred to pH-stat, wherein pH is adjusted to about 6.78. The intestinal digestion step begins when temperature reaches 37 ± 0.5 ℃. pH is adjusted to pH 6.8, and after incubation for two minutes at this pH and temperature, pancreatic enzyme solution (5mM tris, 150mM NaCl, pH 6.8) is added. The final composition of intestinal juice is 10mM CaCl2, 12mM mixed bile salts, 0.75mM phospholipids, 150mM NaCl and 4mM tris (hydroxymethyl) aminomethane buffer. The intestinal digestion step was performed for 3 hours in a titration manager from Radiometer. During the intestinal phase of digestion, the digestion kinetics were followed using pH-stat (TIM856, Radiometer) technology and expressed as titratable acids (rather than fatty acids), which can be calculated by the following formula:
[0241] TA=V NaOH ×0:05×1000
[0242] TA: total titratable acid released, mmol; V NaOH : Volume of NaOH used to titrate the released acid within 3 h, mL.
[0243] 5.6 Results
[0244] Since the digestion of dietary lipids involves lipases from both gastric and intestinal sources, lipid digestibility was assessed using two digestion models: i) simulated intestinal fluid (SIF) containing porcine pancreatic lipase (PPL), and ii) sequential digestion in simulated gastric fluid (SGF) containing rabbit gastric lipase (RGL) followed by simulated intestinal fluid (SIF) containing porcine pancreatic lipase (PPL). All lipids were digested using polyoxyethylene sorbitan monooleate ( 80) for emulsification and have similar particle size distribution and specific surface area ( Figure 2 ), which means that the digestion differences mainly come from the triglyceride molecular structure.
[0245] Figure 1i AC shows the digestion of triglycerides of tributyrin (C4), high oleic sunflower oil (HOSFO, mainly C18:1) and the butyrate-containing fraction according to the invention, generated by chemical transesterification between tributyrin and high oleic sunflower oil (see Example 1) "C4-C18:1" and by porcine pancreatic lipase (from pancreatin) (SIF model) in the presence of mixed bile and calcium. The lipids generally exhibit the same lipolysis behavior, undergoing an initial rapid lipolysis phase within the first 15 minutes, which gradually slows down during the last 2.5 hours of simulated intestinal digestion. The C4 triglycerides exhibited 223±59 μmol.min -1 The initial maximum lipolysis rate of high oleic sunflower oil was 34.5±2.3μmol.min -1 Significantly lower (p<0.0001) than short-chain triglycerides. C4-C18:1 showed 153±47μmol.min -1 The initial hydrolysis rate of C4:1 was between that of C18:1. Overall, it can be seen that all triglycerides were rapidly and extensively digested in the presence of porcine pancreatic lipase.
[0246] Next, the triglyceride digestion was performed using the sequential SGF(RGL)SIF(PPL) model. The digestion in the SIF compartment is shown in Figure 1 ii AC. Measurements were not made in the gastric compartment due to limited ionization of the target fatty acids. C4 and C18:1 triglycerides generally released lower amounts of titratable acid during the 3 h digestion period compared to when digested with SIF alone. The effect was greatest with tributyrin, with an initial lipolysis rate of 223 ± 59 μmol.min when digested with SIF alone. -1 In comparison, the initial lipolysis rate during SGF-SIF digestion was 44.1 ± 8.8 μmol.min -1 Significantly reduced (p<0.0001). The total amount of acid released after SGF-SIF digestion of tributyrin, 381±20 μmol, was almost 1 / 3 of the amount released after SIF digestion alone, 958±12.5 μmol. These results clearly indicate that there is extensive digestion of tributyrin in the gastric compartment of the model.
[0247] When exposed to SGF and SIF sequentially, the SIF lipolysis rate of triglycerides C4-C18:1 containing butyrate moieties was 124 ± 20 μmol.min -1 , compared with SIF alone (124 ± 20 μmol.min -1) showed a slight but insignificant decrease compared to the control group. The most interesting observation was the effect of secondary fatty acid chain length on the reduction in SIF lipolysis caused by RGL pre-exposure. Initially, tributyrin showed a 60.2% (147 ± 7.6 μmol) reduction in total fatty acid release during SIF lipolysis after pre-exposure to RGL in SGF. In contrast, C4-C18:1 interesterified triglycerides showed a 6.1% (45 ± 7.6 μmol) reduction.
[0248] Figure 2 The overall extent of lipid digestion after both SIF and SGF-SIF for three triglycerides using direct titration and reverse titration is shown in Figure 2. Because many fatty acids are only partially ionized at pH 6.8, direct titration only gives a partial picture of the extent of lipid digestion, and reverse titration to pH 11.5 or GC-FAME analysis is required to estimate the extent of complete digestion. The reverse titration results of the three triglycerides show that tributyrin and triglyceride C4-C18:1 containing a butyrate moiety experienced 101.5 ± 0.9% and 101 ± 1.6% digestion, respectively, indicating that three fatty acids are released per molecule for complete digestion, while high oleic sunflower oil experienced 72.3 ± 2% digestion, indicating that two fatty acids are released per molecule for complete digestion.
[0249] In general, it can be seen that tributyrin undergoes extensive hydrolysis in the stomach, while high oleic sunflower oil triglycerides undergo very limited hydrolysis in the stomach. Surprisingly, it can be seen that triglycerides containing a butyrate moiety generated by transesterification of C4 with long-chain fatty acids (C4-C18:1) reduce the extent of gastric lipolysis of C4 fatty acids. Tributyrin undergoes approximately 60% lipolysis by gastric lipase, as indicated by a reduction in total fatty acid release during SIF lipolysis after pre-exposure to RGL in SGF. In contrast, triglycerides containing a butyrate moiety in C4-C18:1 showed only a 6.1% reduction in total fatty acid release in SGF-SIF. These results indicate that transesterification of C4 with long-chain fatty acids (C4-C18:1) regulates the release of butyric acid in the stomach, followed by release in the intestine after digestion, and that the design of structural lipids changes the timing (but not the extent) of delivery of short-chain fatty acids in the gastrointestinal tract.
Claims
1. A compound having the formula or their combination for use in the preparation of a medicament for treatment, Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
2. A compound having the formula or a combination thereof for the preparation of a medicament for treating inflammatory bowel disease such as Crohn's disease or ulcerative colitis, Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Independently a long chain fatty acid having 16 to 20 carbons.
3. The use according to claim 1 or 2, wherein a combination of a compound of formula (1) and a compound of formula (2) is used, preferably wherein the combination is present in a composition comprising a compound of formula (1) and a compound of formula (2), the amount of the compound of formula (1) being at least 10% by weight of the total triglycerides in the composition, and the amount of the compound of formula (2) being at least 10% by weight of the total triglycerides in the composition.
4. The use according to claim 1 or 2, wherein a combination of a compound of formula (1) and a compound of formula (2) is used, and wherein the combination is present in a composition comprising a compound of formula (1) and a compound of formula (2), the amount of the compound of formula (1) being at least 10% by weight of the total butyrate-containing triglycerides in the composition, and the amount of the compound of formula (2) being at least 10% by weight of the total butyrate-containing triglycerides in the composition.
5. The use according to any one of claims 1 to 4, wherein a combination of a compound of formula (1), a compound of formula (2), a compound of formula (3) and a compound of formula (4) is used.
6. The use according to any one of claims 1 to 5, wherein R 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 is an unsaturated fatty acid, preferably a monounsaturated fatty acid, or wherein R 1 , R 2 , R 3 , R 4 , R 5 and / or R 6 Selected from oleic acid, palmitic acid or linoleic acid, or wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Each of which is oleic acid.
7. Use of a composition for the preparation of a medicament for treatment, the composition comprising a compound having the formula wherein the compound of formula (5) comprises at least 10 weight % of the total triglycerides in the composition, and wherein the compound of formula (6) comprises at least 10 weight % of the total triglycerides in the composition.
8. Use of a composition for the preparation of a medicament for treating inflammatory bowel disease such as Crohn's disease or ulcerative colitis, the composition comprising a compound having the formula wherein the compound of formula (5) comprises at least 10 weight % of the total triglycerides in the composition, and wherein the compound of formula (6) comprises at least 10 weight % of the total triglycerides in the composition.
9. A composition according to claim 7 or 8, wherein the compound of formula (5) accounts for at least 15% by weight of the total triglycerides in the composition, and wherein the compound of formula (6) accounts for at least 20% by weight of the total triglycerides in the composition.
10. A composition according to any one of claims 7 to 9, further comprising a compound having the formula Preferably, the compound of formula (7) accounts for at least 2% by weight of the total triglycerides in the composition, and / or further comprises a compound of formula Preferably, the compound of formula (8) comprises at least 2 wt% of the total triglycerides in the composition.
11. Use of a composition for the preparation of a medicament for treatment, the composition comprising a compound having the formula wherein the compound of formula (5) comprises at least 10 weight percent of the total butyrate-containing triglycerides in the composition, and wherein the compound of formula (6) comprises at least 10 weight percent of the total butyrate-containing triglycerides in the composition.
12. Use of a composition for the preparation of a medicament for treating inflammatory bowel disease such as Crohn's disease or ulcerative colitis, the composition comprising a compound having the formula wherein the compound of formula (5) comprises at least 10 weight percent of the total butyrate-containing triglycerides in the composition, and wherein the compound of formula (6) comprises at least 10 weight percent of the total butyrate-containing triglycerides in the composition.
13. A composition according to claim 11 or 12, wherein the compound of formula (5) accounts for at least 15% by weight, preferably at least 20% by weight of the total butyrate-containing triglycerides in the composition, and wherein the compound of formula (6) accounts for at least 20% by weight, preferably at least 25% by weight of the total butyrate-containing triglycerides in the composition.
14. The composition according to any one of claims 11 to 13, further comprising the compound of formula (7), preferably wherein the compound of formula (7) accounts for at least 2% by weight of the total butyrate-containing triglycerides in the composition, and / or further comprising the compound of formula (8), preferably wherein the compound of formula (8) accounts for at least 2% by weight of the total butyrate-containing triglycerides in the composition.
15. The composition according to any one of claims 7 to 14, further comprising 1,3-dibutyryl-2-linoleoyl glycerol, 1,3-dibutyryl-2-stearoyl glycerol, 1-butyryl-2-oleoyl-3-palmitoyl glycerol, 1-palmitoyl-2-oleoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-linoleoyl glycerol, 1-linoleoyl-2-oleoyl-3-butyryl glycerol, 1-oleoyl-2-butyryl-3-linoleoyl glycerol, 1-linoleoyl-2-oleoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-linoleoyl glycerol, 1-linoleoyl-2-butyryl-3-oleoyl glycerol, 1-butyryl- -2-linoleoyl-3-oleoyl glycerol, 1-oleoyl-2-linoleoyl-3-butyryl glycerol, 1-butyryl-2-stearoyl-3-oleoyl glycerol, 1-oleoyl-2-stearoyl-3-butyryl glycerol, 1-butyryl-2-oleoyl-3-stearoyl glycerol, 1-stearoyl-2-oleoyl-3-butyryl glycerol, 1,2-dioleoyl-3-palmitoyl glycerol, 1-palmitoyl-2,3-dioleoyl glycerol, 1,2-dioleoyl-3-linoleoyl glycerol and / or 1-linoleoyl-2,3-dioleoyl glycerol.
Citation Information
Patent Citations
Method and apparatus for maintaining the concentration of a liquid developing solution, in particular for a developing process using the semi-wet method
EP0002020A1
